Mosunetuzumab: an effective treatment for lymphoma patients after relapse?

Written by Heather Jones, Future Science Group

A continuous study has revealed that the immunotherapy mosunetuzumab could put non-Hodgkin lymphoma patients into remission after multiple other therapies, including CAR-T, have failed. The global, multicenter trial has revealed that mosunetuzamab is effective in treating patients with non-Hodgkin lymphoma after relapse, with almost half of those with slow growing lymphomas achieving complete remission. Stephen Schuster from the University of Pennsylvania (PA, USA) will present the results at the American Society of Hematology Annual Meeting and Exposition (7–10 December, FL, USA). Approximately 85% of non-Hodgkin lymphoma cases are B-cell lymphomas. Though many of these patients respond to chemotherapy, those who...

To view the full article, please register now for access

It's completely free